Concept
Outcomes measured in 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
-
Primary: all-cause mortality within 28 day-followup
-
Secondary outcomes:
- Time to discharge
- New use of invasive ventilation
- Death
- Cause-specific mortality
- Use of renal hemodialysis/hemofiltration
- Major cardiac arrhythmia
- Use and duration of ventilation
0
1
Updated 2020-06-26
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Outcomes measured in 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
Randomization and treatment in 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial